Medical News Today -
13 Sep 2013 11:00
Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, has announced that the five-year follow-up of patients with high-risk malignancies from its Phase I/II clinical study confirms long-term safety and efficacy of ATIR(TM) over a broad dose range. ATIR(TM) is a cell-based product designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors for patients who do not have a standard of care stem cell donor av...
Share this Article